Affymetrix's Revenue Guidance Tops Ests - Analyst Blog


Shares of Santa Clara, Calif.-based biomedical company Affymetrix Inc. ( AFFX ) spiked 11.5% following the release of its 2013-fourth quarter revenue guidance that exceeded estimates. Shares of the company closed at $8.81, represented a whopping one-year return of nearly 160.0%.

AFFX revealed that it anticipates fourth quarter revenues of $91.0 million, including a one-time licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013, the company expects total revenue of roughly $329.0 million.

Both the quarterly and annual estimates surpassed the Zacks Consensus Estimate of $85 million and $322 million, respectively. The quarterly sales also reflect a 7.8% rise from the year-ago level of $84.4 million.

Affymetrix posted adjusted earnings per share of 5 cents in the third quarter of 2013, surpassing the Zacks Consensus Estimate of 2 cents and rebounding from the year-ago adjusted loss of 3 cents.

Revenues inched up 0.9% to $80.4 million, beating the Zacks Consensus Estimate of $79 million. Product revenues improved 2.9% to $74.8 million, while Service and other revenues dropped 18.8% to $5.6 million in the reported quarter.

Gross margin surged 300 basis points (bps) to 55% from 52% in the third quarter of 2012. However, on an adjusted basis, gross margin increased 100 bps to 61%.

We believe that AFFX is ready for a turn around and the worst days are over for the company. In the face of declining demand for Affymetrix' flagship GeneChip Expression products, management strategy to transform AFFX into a company with a broad reach in the high-growth markets for translational medicine, molecular diagnostics and applied markets is indeed encouraging.

Currently, AFFX retains a Zacks Rank #1 (Strong Buy). Other players in the biomed/gene industry, which also look attractive at present, include Alimera Sciences, Inc. ( ALIM ), Genomic Health Inc. ( GHDX ), and Horizon Pharma, Inc. ( HZNP ). All of them carry a Zacks Rank #1 (Strong Buy).

AFFYMETRIX INC (AFFX): Free Stock Analysis Report


GENOMIC HEALTH (GHDX): Free Stock Analysis Report

HORIZON PHARMA (HZNP): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: AFFX , ALIM , GHDX , HZNP

More from

Related Videos

Boat Buying Checklist
Boat Buying Checklist               



Most Active by Volume

  • $16.62 ▼ 1.89%
  • $5.5599 ▼ 0.89%
  • $8.17 ▼ 0.37%
  • $17.355 ▼ 2.72%
  • $125.695 ▼ 0.24%
    $18.32 unch
  • $6.8498 ▼ 3.93%
  • $107.9767 ▲ 0.26%
As of 7/7/2015, 03:01 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by